Dubai, UAE – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of South Africa-headquartered Aspen Pharmacare Holdings Limited, has entered into an exclusive licensing agreement (“Agreement”) with UK-based specialist pharmaceutical company Viramal Limited (“Viramal”) for an innovative Women’s Health portfolio.
Under the agreement, Aspen will have exclusive rights to launch and commercialize selected products from Viramal’s portfolio in Europe, the Middle East, Brazil and Mexico.
Daniel Vella Friggieri, Regional CEO – Aspen Europe & Middle East, said, “This agreement underscores Aspen’s continued commitment to advancing innovation across Europe and the Middle East. We are proud to partner with Viramal to further strengthen our Women’s Health portfolio by providing women with access to a broader range of therapies, including enhanced formulations designed to address significant unmet needs.”
Oliver Bates, CEO of Viramal, commented, “We are delighted to partner with Aspen, whose commitment to innovation in Women’s Health aligns perfectly with our mission. The collaboration leverages Viramal’s Fem Med Tech™ platform, a proprietary and patent-protected suite of formulation and drug delivery technologies targeting unmet needs in Women’s Health.
The significant efforts made by Viramal’s women-led development team, under the direction of Dr. Simona Fiore, Chief Medical Officer, have resulted in a range of innovative products. By partnering with Aspen, we can deliver better options to patients across the licensed territories. Aspen’s commitment to Women’s Health is commendable, and we look forward to bringing our portfolio to the market through this partnership.”
Daniel Vella Friggieri, Regional CEO – Aspen Europe & Middle East
Oliver Bates, CEO – Viramal
Firas Nabulsi, Head of Business Development and Marketing – Aspen Europe & Middle East
Issued by:
Firas Nabulsi, Aspen Europe & Middle East Head of Business Development and Marketing
Tel: +971 4 363 4932 | fnabulsi@ae.aspenpharma.com
On behalf of:
Daniel Vella Friggieri, Aspen Europe & Middle East Regional CEO
Tel: +971 4 363 4925 | dvella@ae.aspenpharma.com
About Aspen
Headquartered in Durban, South Africa, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets.
Aspen employs more than 9,500 employees at 66 established offices in over 48 countries and territories. The Group operates 24 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the world’s most stringent regulatory agencies.
Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and regional brands covering both hospital and consumer markets.
The Group’s key business segments are manufacturing and commercial pharmaceuticals, comprising injectable products, prescription and OTC medicines.
For more information, visit www.aspenpharmaeme.com
About Viramal
Headquartered in London, with a branch office within the Medicon Valley, Sweden, Viramal was established in 2013 by an Anglo-Scandinavian partnership with significant expertise in the women’s health sector, in particular reproductive endocrinology.
The Viramal Group is now developing a portfolio of proprietary products using its Fem Med Tech™ platform, targeting the unmet needs of women’s healthcare.
For more information, visit www.viramal.com.
